Hospira Sues FDA Over Generic Precedex ‘Carve-Out’ Approval

Generic Line
Hospira has won a temporary restraining order blocking Mylan from marketing a generic version of its sedative Precedex, which the FDA authorized last week under the controversial section viii statement pathway that foregoes a patent challenge and instead allows manufacturers to “carve out” indications not protected by patents.

To View This Article:


Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00